



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	5	Attorney Docket Number	STAN-213CIP <i>RLX/DRW</i>

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
RLI		ALTENBACH, et al. "Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: A site-directed spin-labeling study", Biochemistry Vol. 35(38): 12470-12478 (1996).				
		ARINS, et al. "A conserved carboxylic acid group mediates light-dependent proton uptake and signaling by rhodopsin", J. Biol. Chem. Vol. 269: 23879-23881 (1994).				
		BERTIN, et al. "Cellular Signaling by an Agonsit-activated receptor/Gsa Fusion Protein", Proc. Natl. Acad. Sci. USA, (1994) Vol. 91: 8827-8831.				
		BOND, et al. "Do Recent Operational Studies Indicate That a Single State Model Is No Longer Applicable to G Protein-Coupled Receptors?", Annals of New York Acad Sci. .., (1997) Vol. 812: 92-97.				
		CHIDIAC, et al. "Agonist-induced modulation of Inverse Agonsit Efficacy at the β_2 -Adrenergic Receptor", Molecular Pharmacology, 50: 662-669 (1996).				
		DUNHAM, et al. "Conformational changes in rhodopsin", J. Biol. Chem. Vol. 274: 1683-1690 (1999).				
RLI		FARAHBAKHS, et al. "Photoactivated conformational changes in rhodopsin: A time-resovled spin label study", Science Vol. 262: 1416-1419 (1993).				

Examiner Signature	<i>RLX/DRW</i>	Date Considered	9/27/2004
--------------------	----------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	10/692,071
				Filing Date	October 22, 2003
				First Named Inventor	KOBILKA, BRIAN K.
				Group Art Unit	1653
				Examiner Name	Not Yet Assigned <i>Reviewing</i>
Sheet	2	of	5	Attorney Docket Number	STAN-213CIP

<i>RL</i>	FARRENS, et al. "Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin", Science Vol. 274(5288): 768-770 (1996).
	FRAUENFELDER, et al. "The energy landscapes and motions of proteins", Science Vol. 254: 1598-1603 (1991).
	FREIRE. "Can allosteric regulation be predicted from structure?", PNAS Vol. 97(22): 11680-11682 (2000).
	GETHER, et al. "Fluorescent Labeling of Purified β_2 Adrenergic Receptor", Biochem., (1996) Vol. 35: 14040-14046.
	GETHER, et al. "Agonists induce Conformational Changes in Transmembrane Domains III and VI of the β_2 Adrenoceptor", The EMBO Journal Vol. 16 No.22 pgs 6737-6747 (1994).
	GETHER, et al. "Fluorescent labeling of purified β_2 adrenergic receptor", J. Biol. Chem. Vol. 270(47): 28268-28275 (1995).
	GETHER, et al. "Agonists induce conformational changes in transmembrane domains III and VI of the β_2 receptor", EMBO J. Vol. 16(22): 6737-6747 (1997).
	GHANOUNI, et al. "The effect of pH on β_2 adrenoceptor function", J. Biol. Chem. Vol. 275: 3121-3127 (2000).
	GHANOUNI, et al. "Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor", Proc. Natl. Acad. Sci. USA, (2001) Vol. 98(11): 5997-6002.
	GHANOUNI, et al. "Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor", J. Biol. Chem., (2001) Vol. 276(27): 24433-24436.
	GILMAN. "G Proteins: transducers of receptor-generated signals", Annu. Rev. Biochem. Vol. 56: 615-649 (1987).
	GINTY. "Calcium regulation of gene expression: Isn't that spatial?", Neuron Vol. 18: 183-186 (1997).
	GUDELMANN, et al. "Functional and structural complexity of signal transduction via G Protein-coupled receptors", Annu. Rev. Neurosci. Vol. 20: 399-427 (1997).
	HAMM. "The many faces of G-Protein signaling", The Journal of Biological Chemistry Vol. 273: 669-672 (1998).
<i>RL</i>	HOPKINSON, et al. "Non-Competitive Anagonism of β_2 -Agonsit-Mediated Cyclic AMP Accumulation by ICI 118551 in BC3H1 Cells Endogenously Expressing Constitutively Active β_2 -Adrenoceptors", British Journal of Pharmacology, 131: 124-130 (2000).

Examiner Signature	<i>Reviewing</i>	Date Considered	9/27/2004
--------------------	------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	5	Application Number	10/692,071
				Filing Date	October 22, 2003
				First Named Inventor	KOBILKA, BRIAN K.
				Group Art Unit	1653
				Examiner Name	Net Yet Assigned <i>Kuixiang Li</i>
				Attorney Docket Number	STAN-213CIP

<i>KL</i>	HOSHI, et al. "Shaker Potassium channel gating I: Transitions near the open state", J. Gen. Physiol. Vol. 103(2): 249-278 (1994).
	JENSEN, et al. "Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling", J. Biol. Chem., (2001) Vol. 276(12): 9279-9290.
	JI, et al. "G-Protein coupled receptors", The Journal of Biological Chemistry Vol. 273: 17229-17302 (1998).
	KENAKIN. "The classification of seven transmembrane receptors in recombinant expression systems", Pharmacological Review Vol. 48: 413-463 (1996).
	KENAKIN. "Agonist-specific receptor conformations", Trends Pharmacol. Sci. Vol. 18(11): 416-417 (1997).
	KOBILKA. "The role of cytosolic and membrane factors in processing of the human β -2 adrenergic receptor following translocation and glycosylation in a cell-free system", J. Biol. Chem. Vol. 265(13): 7610-7618 (1990).
	KOBILKA. "Amino and carboxyl terminal modifications to facilitate the production and purification of a G-Protein-coupled receptor", Anal. Biochem. Vol. 231(1): 269-271 (1995).
	KRUMINS, et al. "The stability of the agonist β_2 -Adrenergic receptor-G _s complex: Evidence for agonist-specific states", Mol. Pharmacol. Vol. 52(1): 144-154 (1997).
	LEE, et al. "Restricting the mobility of G _{sa} : Impact on receptor and effector coupling", Biochemistry Vol. 38: 13801-13809 (1999).
	LEFF. "The two-state model of receptor activation", TiPS Vol. 16: 89-97 (1995).
	LEFKOWITZ, et al. "Adenylate cyclase-coupled beta-adrenergic receptors: Structure and mechanisms of activation and desensitization", Ann. Rev. Biochem. Vol. 52: 159-186 (1983).
	LEFKOWITZ, et al. "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins", TiPS Vol. 14: 304-307 (1993).
	MATKO, et al. "Luminescence quenching by nitroxide spin labels in aqueous solution: Studies on the mechanism of quenching", Biochemistry Vol. 31: 703-711 (1992).
	PALCZEWSKI, et al. "Crystal structure of rhodopsin: A G-Protein-coupled receptor", Science Vol. 289: 739-745 (2000).
<i>KL</i>	PAROLA, et al. "Site-specific fluorescence labeling of the β_2 adrenergic receptor amino terminus", Anal. Biochem. Vol. 254: 88-95 (1997).

Examiner Signature	<i>R. K. Li</i>	Date Considered	7/21/2014
--------------------	-----------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	4	of	5	Attorney Docket Number	STAN-213CIP

RLI	PEREZ, et al. "Constitutive activation of a single effector pathway: Evidence for multiple activation states of a G Protein-coupled receptor", Mol. Pharmacol. Vol. 49(1): 112-122 (1996).
	PETER MOMBAERTS "Seven-Transmembrane Proteins as Odorant and Chemosensory Receptors", Science Vol. 286 (1999) pgs 707-711.
	REMMERS, et al. "Partial G Protein Activation by Fluorescent Guanine Nucleotide Analogs", The Journal of Biological Chemistry, (1996) Vol. 271, No. 9: pgs 4791-4797.
	SAKMAR. "Rhodopsin: A prototypical G-Protein-coupled receptor", Progress in Nucleic Acid Research and Molecular Biology Vol. 59: 1-34 (1998).
	SALAMON, et al. "Plasmon resonance studies of agonist/antagonist binding to the human δ -opioid receptor: New structural insights into receptor-ligand interactions", Biophysical Journal Vol. 79: 2463-2474 (2000).
	SAMAMA, et al. "A mutation-induced activation state of the β_2 -adrenergic receptor", Journal of Biological Chemistry Vol. 268(7): 4625-4636 (1993).
	SCHMIDT. "One-step affinity purification of bacterially produced proteins by means of the "Strep tag" and immobilized recombinant core streptavidin", Journal of Chromatography Vol. 676: 337-345 (1994).
	SEIFERT, et al. "Reconstitution of β_2 -Adrenoceptor-GTP-Binding-Protein Interaction in SF9 Cells High Coupling efficiency in a β_2 -Adrenoceptor-G _{sa} Fusion Protein", Eur J. Biochem., 255: 369-382 (1998).
	SELLEY, et al. " μ -Opioid receptor-stimulated guanosine-5'-O-(γ -thio)-triphosphate binding in rat thalamus and cultures cell lines: signal transduction mechanisms underlying agonist efficacy", Mol. Pharmacol. Vol. 51(1): 87-96 (1997).
	SHEIKH, et al. "Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F", Nature Vol. 383: 347-350 (1996).
	STAMMERS, et al. "Rapid purification and characterization of HIV-1 reverse transcriptase and RNaseH engineered to incorporate a C-terminal tripeptide α -tubulin epitope", FEBS Vol. 283: 298-302 (1991).
	STRADER, et al. "Structure and function of G Protein-coupled receptors", Annu. Rev. Biochem. Vol. 63: 101-132 (1994).
RLI	STRANGE. "G-Protein coupled receptors", Biochem. Pharmacol. Vol. 58(7): 1081-1088 (1999).

Examiner Signature	RLI	Date Considered	9/27/2004
--------------------	-----	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	5	of	5	Attorney Docket Number	STAN-213CIP
RuiXiang Li					

RuiXiang Li	STRANGE P. G. "Agonism and Inverse Agonism at Dopamine D ₂ -Like Receptors", Clinical and Experimental Pharm and Physio., 26 (Suppl) S3-S9 (1999).
	SUBRAMANIAM, et al. "Molecular mechanism of vectorial proton translocation by bacteriorhodopsin", Nature Vol. 406: 653-657 (2000).
	TOTA, et al. "Partial agonist effects on the interaction between the atrial muscarinic receptor and the inhibitory guanine nucleotide-binding protein in a reconstituted system", Mol. Pharmacol. Vol. 37(6), 996-1004 (1990).
↓	TUCEK. "Is the R and R* dichotomy real?", TiPS. Vol. 18(11): 414-416 (1997).
RuiXiang Li	YANG, et al. "Structure and function in rhodopsin. Cysteines 65 and 316 are in proximity in a rhodopsin mutant as indicated by disulfide formation and interactions between attached spin labels", Biochem., (1996) Vol. 35: 14040-14046.

Examiner Signature	RuiXiang Li	Date Considered	9/27/2004
--------------------	-------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.